Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting…
Oncology
-
-
Teva and mAbxience partner to develop biosimilar candidate for oncology
Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein…
-
BMS receives FDA approval for Opdivo to treat NSCLC
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults…
-
Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies
Enara Bio has raised $32.5m in a Series B financing round to advance its platform shining a light on cancer-specific…
-
ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer
ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer and evaluation agreement (MTEA) with…
-
Shattuck Labs stock craters following pipeline and job cuts
Shattuck Labs has dropped by nearly 45% after it announced plans to reduce its headcount and discontinue its lead cancer…
-
Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec
Amid the boom in the radiopharmaceutical space, peptide-based therapeutics could be set to outmanoeuvre antibody-based counterparts, according to WuXi AppTec’s…
-
Aktis Oncology raises $175m to advance radiopharmaceutical pipeline
Aktis Oncology, a clinical-stage biotechnology company, has announced the successful closure of a $175m Series B financing round for advancing…
-
Tempus AI expands oncology collaboration with Takeda
Tempus AI has announced an expanded collaboration with Takeda to enhance oncology research and development. The partnership aims to leverage…
-
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated…
